Correlation Between Quantitative HER-2 Protein Expression and Risk for Brain Metastases in HER-2+ Advanced Breast Cancer Patients Receiving Trastuzumab-Containing Therapy

RENATA DUCHNOWSKA, WOJCIECH BIERNAT, BARBARA SZOSTAKIEWICZ, JEFF SPERINDE, FANNY PIETTE, MOJGAN HADDAD, AGNES PAQUET, YOLANDA LIE, BOGUMIŁA CZARTORYSKA-ARŁUKOWICZ, PIOTR WYSOCKI, TOMASZ JANKOWSKI, BARBARA RADECKA, MAŁGORZATA FOSZCZYŃSKA-KŁODA, MARIA LITWINIUK, SYLWIA DĘBSKA, JODI WEIDLER, WEIDONG HUANG, MARC BUYSE, MICHAEL BATES, JACEK JASSEM

The Oncologist 2012;17:26-35; doi:10.1634/theoncologist.2011-0212

Due to an editing error, the affiliation for Sylwia Dębska was incorrectly identified. Dr. Dębska is affiliated with the Medical University of Łódź, Poland. The publisher regrets this error.

Perspectives on Treatment of Metastatic Castration-Resistant Prostate Cancer

AXEL S. MERSEBURGER, JOAQUIM BELLMUNT, CHERYL JENKINS, CHRIS PARKER, JOHN M. FITZPATRICK, ON BEHALF OF THE EUROPEAN TREATMENT PRACTICES GROUP

The Oncologist 2013;18:558-567; doi:10.1634/theoncologist.2012-0478

Due to a production error, figure 2 was misprinted. The corrected figure appears below. The publisher regrets this error.

Figure 2. Current and possible future sequencing of drugs in castration-resistant prostate cancer in Europe. Abbreviations: GnRH, gonadotropin-releasing hormone; LHRH, luteinizing hormone-releasing hormone; mCRPC, metastatic castration-resistant prostate cancer.